Jefferies downgraded Gerresheimer AG from Buy to Hold on Tuesday.
The investment bank slashed the price target to €26.80 from €34.10.
Analysts cited growing concerns over delayed financial results and persistent market overhangs.
The firm highlighted increased execution risks regarding the Bormioli Pharma acquisition.
Jefferies expects synergy realization to be slower and more costly than initially anticipated.
Repeated reporting delays have weakened investor confidence and prompted higher valuation discounts.
These challenges justify a lower valuation relative to peers and the broader market.